Cargando…

Emerging agents and regimens for AML

Until recently, acute myeloid leukemia (AML) patients used to have limited treatment options, depending solely on cytarabine + anthracycline (7 + 3) intensive chemotherapy and hypomethylating agents. Allogeneic stem cell transplantation (Allo-SCT) played an important role to improve the survival of...

Descripción completa

Detalles Bibliográficos
Autor principal:	Liu, Hongtao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989091/ https://www.ncbi.nlm.nih.gov/pubmed/33757574 http://dx.doi.org/10.1186/s13045-021-01062-w

Ejemplares similares

Emerging agents and regimens for multiple myeloma
por: Yang, Yang, et al.
Publicado: (2020)

Emerging agents and regimens for hepatocellular carcinoma
por: Zhu, Xiao-Dong, et al.
Publicado: (2019)

Rational Combinations of Targeted Agents in AML
por: Bose, Prithviraj, et al.
Publicado: (2015)

Emerging agents and regimens for polycythemia vera and essential thrombocythemia
por: Shallis, Rory M., et al.
Publicado: (2021)

Clinical Results of Hypomethylating Agents in AML Treatment
por: Cruijsen, Marjan, et al.
Publicado: (2014)

Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial
por: Liu, Yifan, et al.
Publicado: (2023)

New agents in acute myeloid leukemia (AML)
por: Park, Silvia, et al.
Publicado: (2020)

Emerging CAR T Cell Strategies for the Treatment of AML
por: Vishwasrao, Paresh, et al.
Publicado: (2022)

Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting
por: Hou, Jing-Zhou, et al.
Publicado: (2021)

Treatment of Low-Blast Count AML using Hypomethylating Agents
por: De Bellis, Eleonora, et al.
Publicado: (2017)

AML under the Scope: Current Strategies and Treatment Involving FLT3 Inhibitors and Venetoclax-Based Regimens
por: Milnerowicz, Szymon, et al.
Publicado: (2023)

Risk of infection in elderly patients with AML and MDS treated with hypomethylating agents
por: Livio, Pagano, et al.
Publicado: (2018)

Prospective Randomization Trial of G-CSF-Primed Induction Regimen versus Standard Regimen in Patients with AML
por: Lee, Yoo Jin, et al.
Publicado: (2011)

Regimen‐intensity per count‐recovery and hospitalization index: A new tool to assign regimen intensity for AML
por: Sorror, Mohamed L., et al.
Publicado: (2020)

Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents
por: Halik, Adriane, et al.
Publicado: (2022)

New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML)
por: Chen, Jing, et al.
Publicado: (2020)

Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens
por: Castaño-Bonilla, Tamara, et al.
Publicado: (2021)

Clofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML
por: Ramaswamy, Kavitha, et al.
Publicado: (2022)

P582: AZACITIDINE COMBINED WITH HAG REGIMEN AS INDUCTION THERAPY IN ADULT AML PATIENTS
por: Pan, Hong, et al.
Publicado: (2023)

Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML
por: Kubasch, Anne Sophie, et al.
Publicado: (2018)

Inhaled therapy in cystic fibrosis: agents, devices and regimens
por: Agent, Penny, et al.
Publicado: (2015)

Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study
por: Li, Jing, et al.
Publicado: (2023)

The role of the proteasome in AML
por: Csizmar, C M, et al.
Publicado: (2016)

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML
por: Cao, Xing-yu, et al.
Publicado: (2023)

Securinine, a Myeloid Differentiation Agent with Therapeutic Potential for AML
por: Gupta, Kalpana, et al.
Publicado: (2011)

Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen
por: Schmutz, Maximilian, et al.
Publicado: (2023)

Current and Emerging Techniques for Diagnosis and MRD Detection in AML: A Comprehensive Narrative Review
por: Teixeira, Alexandra, et al.
Publicado: (2023)

New agents and regimens for diffuse large B cell lymphoma
por: Wang, Liang, et al.
Publicado: (2020)

SIMILAR OUTCOMES USING MYELOABLATIVE VERSUS REDUCED INTENSITY ALLOGENEIC TRANSPLANT PREPARATIVE REGIMENS FOR AML OR MDS
por: Luger, Selina M., et al.
Publicado: (2011)

Targeting mTOR for the treatment of AML. New agents and new directions
por: Altman, Jessica K., et al.
Publicado: (2011)

Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights
por: Zhu, Xiongpeng, et al.
Publicado: (2010)

P1390: THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED REGIMEN FOR ALLOGENEIC TRANSPLANTATION IN REFRACTORY/RELAPSED AML PATIENTS
por: Chen, S., et al.
Publicado: (2022)

The Challenge of AML in Older Patients
por: Burnett, Alan K
Publicado: (2013)

Treatments for children and adolescents with AML
por: Kim, Hyery
Publicado: (2020)

Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence
por: Stemer, Galia, et al.
Publicado: (2021)

Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
por: Chen, Evan C, et al.
Publicado: (2018)

Aberrant splicing and drug resistance in AML
por: de Necochea-Campion, Rosalia, et al.
Publicado: (2016)

Autologous Transplantation for Older Adults with AML
por: Mueller, Beatrice U., et al.
Publicado: (2018)

Role of Biomarkers in FLT3 AML
por: Nitika,, et al.
Publicado: (2022)

Novel Tools for Diagnosis and Monitoring of AML
por: Guijarro, Francesca, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ln4449c5dlu4mf8uo1qd5o3o3l